Skip to main content

Senate bill · S. 4323 (119th Congress)

Ensuring Access to Lower-Cost Medicines for Seniors Act

Latest action Apr 16, 2026

U.S. Senate

Sponsor

James Lankford

U.S. Senator for Oklahoma · Republican

Follow

Summary

Ensuring Access to Lower-Cost Medicines for Seniors Act This bill requires prescription drug plans under the Medicare prescription drug benefit to include generic drugs and biosimilars on their formularies. Specifically, the bill requires plans that use formularies to include generic drugs and biosimilars on the formularies and without any requirements (e.g., prior authorization requirements) that are more restrictive as compared to those for brand-name drugs and biologics. Plans that use cost-sharing tiers must also have specific tiers for generic drugs and biosimilars, in accordance with certain limitations.

Summary from the Congressional Research Service. How we handle summaries

From Congress.gov and official rosters. This record was last updated Sep 8, 2026. About our data

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

Senate Committee on Finance · U.S. Senate

Cosponsors

Showing the cosponsors who are on Agora, A to Z. The official record may list more.

Read on Congress.gov (opens in a new tab)
  • Democratic1

Shown in neutral colors by design; Agora is non-partisan.

Full history

  1. Apr 16, 2026

    Introduced

    Introduced in U.S. Senate

    U.S. Senate

  2. Apr 16, 2026

    Referred to committee

    Read twice and referred to the Committee on Finance.

  3. Apr 16, 2026

    Referred to committee

    Read twice and referred to the Committee on Finance.

  4. Apr 16, 2026

    Referred to committee

    Read twice and referred to the Committee on Finance.